Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Semin Cancer Biol. 2017 Nov 28;52(Pt 2):53–65. doi: 10.1016/j.semcancer.2017.11.009

Figure 1. Potential Biomarkers and therapeutic targets of Neuroblastoma.

Figure 1

Abbreviations: 5-LOX: 5-lipoxygenase, CAI2: CDKN2A/ARF intron 2, CASC15: cancer susceptibility candidate15, COX-2: cyclooxygenase-2, CTLA4: cytotoxic T-lymphocyte associated protein 4, CXCL12: C-X-C motif chemokine 12, CXCR4: C-X-C chemokine receptor 4, FCGR3: Fc fragment of IgG receptor III, GAS5: growth arrest special 5, HCN3: hyperpolarization-activated cation nucleotide-gated isoform 3, HIF-1α: hypoxia-inducible factor 1-alpha, HOXD-AS1: HOXD cluster antisense RNA 1, IRF1: interferon regulatory factor 1, linc00467: long Intergenic non-protein coding RNA 467, linc01105: long intergenic non-protein coding RNA 1105, lncUSMycN: lncRNA upstream of MYCN, MALAT1: metastasis associated lung adenocarcinoma transcript 1, MEG3: maternally expressed 3, miR: microRNA, NBAT1: neuroblastoma associated transcript 1, ncRAN: non-coding RNA expressed in aggressive neuroblastoma, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, PD-1: programmed death-1, PD-L1: programmed death-ligand 1, PD-L2: programmed death-ligand 2, PVT-1: plasmacytoma variant translocation 1, SNHG1: small nucleolar RNA host gene 1, STAT-3: signal transducer and activator of transcription 3, TAMs: tumor-associated macrophages, TNF-α: tumor necrosis factor-alpha, VEGF: vascular endothelial growth factor.